Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Gain Therapeutics (GANX) Return on Sales (2020 - 2023)

Historic Return on Sales for Gain Therapeutics (GANX) over the last 4 years, with Q4 2023 value amounting to 408.79%.

  • Gain Therapeutics' Return on Sales fell 2832400.0% to 408.79% in Q4 2023 from the same period last year, while for Dec 2023 it was 408.79%, marking a year-over-year decrease of 2832400.0%. This contributed to the annual value of 408.79% for FY2023, which is 2832400.0% down from last year.
  • As of Q4 2023, Gain Therapeutics' Return on Sales stood at 408.79%, which was down 2832400.0% from 402.65% recorded in Q3 2023.
  • Gain Therapeutics' Return on Sales' 5-year high stood at 39.89% during Q2 2021, with a 5-year trough of 465.07% in Q1 2021.
  • For the 4-year period, Gain Therapeutics' Return on Sales averaged around 179.17%, with its median value being 105.87% (2023).
  • In the last 5 years, Gain Therapeutics' Return on Sales crashed by -3775100bps in 2021 and then soared by 3923500bps in 2022.
  • Quarter analysis of 4 years shows Gain Therapeutics' Return on Sales stood at 181.17% in 2020, then skyrocketed by 59bps to 74.52% in 2021, then plummeted by -68bps to 125.55% in 2022, then tumbled by -226bps to 408.79% in 2023.
  • Its Return on Sales was 408.79% in Q4 2023, compared to 402.65% in Q3 2023 and 399.75% in Q2 2023.